GLOSSARY

Incretin Degradation reduces active signaling through processing and removal.

The incretin effect is greater insulin secretion after oral than intravenous glucose when glycemia is matched. GLP-1 and GIP are important contributors with nonidentical functions, and glucose dependence of insulin stimulation matters. Natural short-lived hormones are not equivalent to long-acting receptor-agonist drugs. A meal-related hormone change therefore does not reproduce a drug treatment effect or establish inevitable weight loss; physiological exposure and therapeutic exposure must remain distinct.

Nutrient entry, gastric distension and neural and hormonal signals jointly regulate eating. GLP-1, PYY and CCK are important, but one blood rise cannot precisely predict later intake. Molecular form, receptor and vagal or central routes matter. In athletes, strong fullness from low-energy bulky meals can make adequate fueling difficult, so portions and timing should fit actual demand and tolerance rather than pursuing maximal appetite suppression.

Pancreatic islets contain several signaling cell types with important local interactions. Somatostatin can inhibit other secretions, while pancreatic polypeptide and amylin have distinct roles. Amylin is co-secreted with beta-cell insulin and participates in gastric emptying and meal-ending signals. Similar names or simultaneous secretion do not imply identical effects, receptors or drug uses; each signal needs its source and function distinguished within the islet and gut–brain network.

For practical use, record meal and training timing, sleep and hunger alongside actual intake and performance trends. When a marker changes, first examine measurement conditions and plausible explanations; food decisions should support adequate supply, tolerance and recovery rather than ending the assessment at one molecular signal or assuming a concentration change automatically establishes a useful intervention.

Carbohydrate, protein and fat have different digestive and signaling routes that interact in mixed meals. Protein can stimulate both insulin and glucagon; insulin is not simply an added-sugar marker. Fat and fiber can shift timing through gastric-emptying effects. Program quality depends on energy, nutrients, tolerance and fit with training rather than producing the lowest possible hormonal response after every meal or treating physiological insulin secretion as inherently undesirable.

Some exercise, especially hard bouts, can temporarily suppress appetite, but the response varies across people and sessions. Ghrelin, PYY and GLP-1 changes do not have a simple guaranteed relationship with later intake. Lower appetite does not mean lower energy requirements. Athletes can use tolerable foods, smaller portions and workable timing to meet demand and monitor recovery rather than assuming a blunted hunger signal proves that refueling is unnecessary.

Hormonal imbalance is a broad description rather than a standalone diagnosis from an online symptom list. Deficiency, excess and resistance differ, and reference ranges depend on method, age and conditions. Medicines, illness, sleep and energy status also matter. Persistent symptoms need appropriate assessment to identify causes; choosing supplements or manipulating hormones from one isolated test cannot replace evidence-based evaluation or establish a universal athletic hormone target.